Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. The recommendation covers clinically stable adults on 1-month paliperidone palmitate (PP1M) or 3-monthly paliperidone palmitate.
Filed Under: clinical trials, Drug Delivery, Drug Discovery, Drug Discovery and Development, Neurological Disease